Philip Boudreau
Summary
Philip Boudreau is Abbott’s Chief Financial Officer & Executive Vice President of Finance, a role he has held since July 2024 after more than two decades in Abbott finance positions. ([abbott.com](https://www.abbott.com/en-us/about-abbott/leadership/executive-team/phil-boudreau?utm_source=openai))
Biography
Boudreau joined Abbott in 1997 and has held finance and controller positions across several businesses, including Point of Care Diagnostics, Nutrition, Diabetes Care and Medical Devices. Before becoming CFO, he served as Vice President, Finance, and Controller. ([abbott.com](https://www.abbott.com/en-us/about-abbott/leadership/executive-team/phil-boudreau?utm_source=openai)) He holds a management degree from Purdue University and also attended the University of Illinois. Abbott appointed him Executive Vice President, Finance and Chief Financial Officer effective July 1, 2024, making him the company’s principal financial officer. His responsibilities include financial reporting, planning, performance management and supporting Abbott’s capital-allocation and acquisition decisions. ([abbott.com](https://www.abbott.com/en-us/about-abbott/leadership/executive-team/phil-boudreau?utm_source=openai))
Notable achievements
- Built a long Abbott finance career spanning multiple operating segments before becoming CFO. ([abbott.com](https://www.abbott.com/en-us/about-abbott/leadership/executive-team/phil-boudreau?utm_source=openai))
- Advanced to Executive Vice President, Finance and Chief Financial Officer in July 2024 after serving as Senior Vice President, Finance and CFO. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1800/000130817925000134/abt012575_def14a.htm?utm_source=openai))
- Abbott reported $7.4 billion of free cash flow in 2025, above the company’s $6.5 billion incentive-plan target. ([abbottinvestor.com](https://www.abbottinvestor.com/static-files/246b2be3-fa3e-447f-86cc-683aca8371c7?utm_source=openai))
- Abbott’s 2025 gross margin rose to 52.6% from 50.9% in 2024, reflecting margin-improvement initiatives despite higher costs and foreign-exchange pressure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm))
- Supported the financing and reporting work associated with Abbott’s March 2026 acquisition of Exact Sciences, funded primarily through $20 billion of long-term debt. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/abt-20260331.htm?utm_source=openai))
Problem areas / controversies
- Abbott’s 2025 adjusted sales of $43.141 billion were below the $44.161 billion target used in the company’s executive incentive plan, although adjusted EPS met target and free cash flow exceeded target. ([abbottinvestor.com](https://www.abbottinvestor.com/static-files/246b2be3-fa3e-447f-86cc-683aca8371c7?utm_source=openai))
- The Exact Sciences acquisition materially increased Abbott’s debt load, creating integration, interest-cost and leverage risks for the finance organization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/abt-20260331.htm?utm_source=openai))
- Abbott recorded $274 million of employee-related severance and other restructuring charges in 2025 as management streamlined operations across several businesses. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm))
- Public filings reviewed identify no major personal controversy involving Boudreau; the principal public scrutiny around his tenure concerns company-level financial execution, restructuring and acquisition financing.